Although Wnt overexpression may not be responsible for the hyperactive Wnt signaling in human breast cancers, targeting this pathway upstream of mutated APC or β-catenin has also been used since recent evidence suggest that such compounds might be beneficial [16]. The gene discussed is APC; the disease is breast carcinoma.